BACKGROUND: Resveratrol, a plant-derived polyphenol, has shown promising effects on insulin sensitivity and glucose tolerance in animal models and is also reported to have cardioprotective properties, but human studies are limited. In a pilot study, we tested the hypothesis that resveratrol improves glucose metabolism and vascular function in older adults with impaired glucose tolerance (IGT). METHODS:Ten subjects aged 72 ± 3 years (M ± SD) with IGT were enrolled in a 4-week open-label study of resveratrol (daily dose 1, 1.5, or 2 g). Following a standard mixed meal (110 g carbohydrate, 20 g protein, 20 g fat), we measured 3-hour glucose and insulin area under the curve (AUC), insulin sensitivity (Matsuda index), and secretion (corrected insulin response at 30 minutes). Endothelial function was assessed by reactive hyperemia peripheral arterial tonometry (reactive hyperemia index) before and 90 minutes postmeal. Results did not differ by dose, so data were combined for analysis. RESULTS: At baseline, body mass index was 29 ± 5 kg/m(2), fasting plasma glucose 110 ± 13 mg/dL, and 2-hour glucose 183 ± 33 mg/dL. After 4 weeks of resveratrol, fasting plasma glucose was unchanged, but peak postmeal (185 ± 10 vs 166 ± 9 mg/dL, p = .003) and 3-hour glucose AUC (469 ± 23 vs 428 ± 19, p = .001) declined. Matsuda index improved (3.1 ± 0.5 vs 3.8 ± 0.5, p = .03), and corrected insulin response at 30 minutes was unchanged (0.6 ± 0.1 vs 0.5 ± 0.5, p = .49). There was a trend toward improved postmeal reactive hyperemia index (baseline vs resveratrol postmeal delta -0.4 ± 0.2 vs 0.2 ± 0.3, p = .06). Weight, blood pressure, and lipids were unchanged. CONCLUSIONS: At doses between 1 and 2 g/day, resveratrol improves insulin sensitivity and postmeal plasma glucose in subjects with IGT. These preliminary findings support the conduct of larger studies to further investigate the effects of resveratrol on metabolism and vascular function.
RCT Entities:
BACKGROUND:Resveratrol, a plant-derived polyphenol, has shown promising effects on insulin sensitivity and glucose tolerance in animal models and is also reported to have cardioprotective properties, but human studies are limited. In a pilot study, we tested the hypothesis that resveratrol improves glucose metabolism and vascular function in older adults with impaired glucose tolerance (IGT). METHODS: Ten subjects aged 72 ± 3 years (M ± SD) with IGT were enrolled in a 4-week open-label study of resveratrol (daily dose 1, 1.5, or 2 g). Following a standard mixed meal (110 g carbohydrate, 20 g protein, 20 g fat), we measured 3-hour glucose and insulin area under the curve (AUC), insulin sensitivity (Matsuda index), and secretion (corrected insulin response at 30 minutes). Endothelial function was assessed by reactive hyperemia peripheral arterial tonometry (reactive hyperemia index) before and 90 minutes postmeal. Results did not differ by dose, so data were combined for analysis. RESULTS: At baseline, body mass index was 29 ± 5 kg/m(2), fasting plasma glucose 110 ± 13 mg/dL, and 2-hour glucose 183 ± 33 mg/dL. After 4 weeks of resveratrol, fasting plasma glucose was unchanged, but peak postmeal (185 ± 10 vs 166 ± 9 mg/dL, p = .003) and 3-hour glucose AUC (469 ± 23 vs 428 ± 19, p = .001) declined. Matsuda index improved (3.1 ± 0.5 vs 3.8 ± 0.5, p = .03), and corrected insulin response at 30 minutes was unchanged (0.6 ± 0.1 vs 0.5 ± 0.5, p = .49). There was a trend toward improved postmeal reactive hyperemia index (baseline vs resveratrol postmeal delta -0.4 ± 0.2 vs 0.2 ± 0.3, p = .06). Weight, blood pressure, and lipids were unchanged. CONCLUSIONS: At doses between 1 and 2 g/day, resveratrol improves insulin sensitivity and postmeal plasma glucose in subjects with IGT. These preliminary findings support the conduct of larger studies to further investigate the effects of resveratrol on metabolism and vascular function.
Authors: Marie Lagouge; Carmen Argmann; Zachary Gerhart-Hines; Hamid Meziane; Carles Lerin; Frederic Daussin; Nadia Messadeq; Jill Milne; Philip Lambert; Peter Elliott; Bernard Geny; Markku Laakso; Pere Puigserver; Johan Auwerx Journal: Cell Date: 2006-11-16 Impact factor: 41.582
Authors: Catherine C Cowie; Keith F Rust; Danita D Byrd-Holt; Mark S Eberhardt; Katherine M Flegal; Michael M Engelgau; Sharon H Saydah; Desmond E Williams; Linda S Geiss; Edward W Gregg Journal: Diabetes Care Date: 2006-06 Impact factor: 19.112
Authors: Joseph A Baur; Kevin J Pearson; Nathan L Price; Hamish A Jamieson; Carles Lerin; Avash Kalra; Vinayakumar V Prabhu; Joanne S Allard; Guillermo Lopez-Lluch; Kaitlyn Lewis; Paul J Pistell; Suresh Poosala; Kevin G Becker; Olivier Boss; Dana Gwinn; Mingyi Wang; Sharan Ramaswamy; Kenneth W Fishbein; Richard G Spencer; Edward G Lakatta; David Le Couteur; Reuben J Shaw; Placido Navas; Pere Puigserver; Donald K Ingram; Rafael de Cabo; David A Sinclair Journal: Nature Date: 2006-11-01 Impact factor: 49.962
Authors: Jill Crandall; David Schade; Yong Ma; Wilfred Y Fujimoto; Elizabeth Barrett-Connor; Sarah Fowler; Sam Dagogo-Jack; Reubin Andres Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Naomi M Hamburg; Michelle J Keyes; Martin G Larson; Ramachandran S Vasan; Renate Schnabel; Moira M Pryde; Gary F Mitchell; Jacob Sheffy; Joseph A Vita; Emelia J Benjamin Journal: Circulation Date: 2008-05-05 Impact factor: 29.690
Authors: Jill C Milne; Philip D Lambert; Simon Schenk; David P Carney; Jesse J Smith; David J Gagne; Lei Jin; Olivier Boss; Robert B Perni; Chi B Vu; Jean E Bemis; Roger Xie; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Amy V Lynch; Hongying Yang; Heidi Galonek; Kristine Israelian; Wendy Choy; Andre Iffland; Siva Lavu; Oliver Medvedik; David A Sinclair; Jerrold M Olefsky; Michael R Jirousek; Peter J Elliott; Christoph H Westphal Journal: Nature Date: 2007-11-29 Impact factor: 49.962
Authors: Joseph A Baur; Zoltan Ungvari; Robin K Minor; David G Le Couteur; Rafael de Cabo Journal: Nat Rev Drug Discov Date: 2012-06-01 Impact factor: 84.694
Authors: Clémence D Côté; Brittany A Rasmussen; Frank A Duca; Melika Zadeh-Tahmasebi; Joseph A Baur; Mira Daljeet; Danna M Breen; Beatrice M Filippi; Tony K T Lam Journal: Nat Med Date: 2015-04-06 Impact factor: 53.440
Authors: Victoria H J Roberts; Lynley D Pound; Stephanie R Thorn; Melanie B Gillingham; Kent L Thornburg; Jacob E Friedman; Antonio E Frias; Kevin L Grove Journal: FASEB J Date: 2014-02-21 Impact factor: 5.191
Authors: Jesus A Villanueva; Anna Sokalska; Amanda B Cress; Israel Ortega; Kaylon L Bruner-Tran; Kevin G Osteen; Antoni J Duleba Journal: J Clin Endocrinol Metab Date: 2013-02-05 Impact factor: 5.958
Authors: Yolanda Jimenez-Gomez; Julie A Mattison; Kevin J Pearson; Alejandro Martin-Montalvo; Hector H Palacios; Alex M Sossong; Theresa M Ward; Caitlin M Younts; Kaitlyn Lewis; Joanne S Allard; Dan L Longo; Jonathan P Belman; Maria M Malagon; Placido Navas; Mitesh Sanghvi; Ruin Moaddel; Edward M Tilmont; Richard L Herbert; Christopher H Morrell; Josephine M Egan; Joseph A Baur; Luigi Ferrucci; Jonathan S Bogan; Michel Bernier; Rafael de Cabo Journal: Cell Metab Date: 2013-10-01 Impact factor: 27.287